Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Nektar Therapeutics Ownership Summary

Nektar Therapeutics is owned by 67.25% institutional investors, 1.04% insiders, and 31.71% retail investors. Deep track capital, lp is the largest institutional shareholder, holding 9.18% of NKTR shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 4.09% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Nektar Therapeutics	67.25%	1.04%	31.71%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Deep track capital, lp	17.88M	9.18%	$22.17M
Blackrock	15.16M	7.78%	$18.79M
Vanguard group	12.97M	6.66%	$16.08M
Samlyn capital	9.46M	4.86%	$11.73M
Eventide asset management	7.53M	3.87%	$9.34M
Primecap management co/ca/	6.02M	3.09%	$7.47M
Acadian asset management	4.88M	2.51%	$6.05M
Millennium management	4.66M	2.39%	$5.78M
Geode capital management	4.11M	2.11%	$5.10M
Nantahala capital management	4.11M	2.11%	$5.10M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Cm management	750.00K	0.85%	$930.00K
Deep track capital, lp	17.88M	0.66%	$22.17M
Acuitas investments	879.90K	0.58%	$1.09M
Tcg crossover management	4.00M	0.52%	$4.96M
Almitas capital	920.23K	0.47%	$1.14M
Monaco asset management sam	2.17M	0.43%	$2.69M
Shay capital	1.84M	0.32%	$2.28M
Nantahala capital management	4.11M	0.30%	$5.10M
Ikarian capital	1.31M	0.28%	$1.63M
Samlyn capital	9.46M	0.20%	$11.73M

Top Buyers

Holder	Shares	% Assets	Change
Samlyn capital	9.46M	0.20%	9.46M
Blackrock	15.16M	0.00%	9.28M
Eventide asset management	7.53M	0.16%	7.53M
State street	2.99M	0.00%	2.30M
Geode capital management	4.11M	0.00%	2.06M

Top Sellers

Holder	Shares	% Assets	Change
Monaco asset management sam	2.17M	0.43%	-3.67M
Stonepine capital management	-	-	-3.48M
Acadian asset management	4.88M	0.02%	-2.68M
D. e. shaw	346.65K	0.00%	-2.20M
Lynx1 capital management lp	-	-	-2.07M

New Positions

Holder	Shares	% Assets	Change	Value
Samlyn capital	9.46M	0.20%	9.46M	$11.73M
Eventide asset management	7.53M	0.16%	7.53M	$9.34M
Ikarian capital	1.31M	0.28%	1.31M	$1.63M
Armistice capital	836.00K	0.01%	836.00K	$1.04M
Woodline partners lp	622.90K	0.01%	622.90K	$772.40K

Sold Out

Holder	Change
Assetmark	-22.00
Cubist systematic strategies	-40.00
Princeton global asset management	-100.00
Nelson, van denburg & campbell wealth management group	-200.00
Wealthcollab	-300.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	141	3.68%	140,729,035	3.96%	67	1.39%	61	-15.28%	36	5.88%
Jun 30, 2024	136	10.57%	135,373,255	19.87%	69	2.07%	72	94.59%	34	-29.17%
Mar 31, 2024	123	0.82%	112,937,953	-5.21%	57	1.47%	37	-11.90%	48	-
Dec 31, 2023	122	-6.87%	119,146,708	-16.53%	62	1.12%	42	-12.50%	48	11.63%
Sep 30, 2023	131	-10.27%	142,737,229	3.68%	74	1.42%	48	-9.43%	43	-10.42%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	7.53M	4.09%	7.53M
Vanguard Total Stock Mkt Idx Inv	5.72M	3.10%	-
iShares Russell 2000 ETF	5.16M	2.80%	-10.78K
PRIMECAP Odyssey Aggressive Growth	3.69M	2.01%	-
Vanguard Institutional Extnd Mkt Idx Tr	2.66M	1.44%	-255.93K
Fidelity Small Cap Index	1.82M	0.99%	-8.91K
iShares Russell 2000 Value ETF	1.81M	0.98%	2.34K
PRIMECAP Odyssey Growth	1.61M	0.87%	-93.30K
Vanguard Strategic Equity Inv	1.52M	0.82%	-
Bridgeway Ultra-Small Company	1.36M	0.74%	1.36M

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 19, 2024	Zalevsky Jonathan	Chief R&D Officer	Sell	$48.05K
Dec 18, 2024	ROBIN HOWARD W	President & CEO	Sell	$84.18K
Dec 17, 2024	ROBIN HOWARD W	President & CEO	Sell	$47.46K
Nov 19, 2024	Zalevsky Jonathan	Chief R&D Officer	Sell	$7.86K
Nov 19, 2024	Wilson Mark Andrew	Chief Legal Officer	Sell	$6.47K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	6
2024 Q3	-	3
2024 Q2	-	5
2024 Q1	-	3
2023 Q4	-	3

NKTR Ownership FAQ

Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 67.25%, followed by 1.04% insiders and 31.71% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 47.04%, which Nektar Therapeutics exceeds.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Deep track capital, lp (17.88M shares, 9.18%), Blackrock (15.16M shares, 7.78%), and Vanguard group (12.97M shares, 6.66%). Together, they hold 23.62% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

Cm management is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.85% of its assets in 750K Nektar Therapeutics shares, valued at 930K$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Nektar Therapeutics shares, with 4.09% of its total shares outstanding invested in 7.53M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools